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Abstract  
The pregnane x receptor (PXR, NR1I2) is a member of the nuclear receptor 
(NR) superfamily of ligand-activated transcription factors. PXR is activated by 
numerous lipophilic compounds, a variety of drugs and drug metabolites in 
clinical use. It regulates xenobiotic-inducible cytochrome P450 (CYP) 
expression in the liver and intestine which are major organs for xenobiotic 
biotransformation.  While PXR has been identified as the positive regulator of 
many drug metabolizing enzymes (DMEs) and membrane transporter proteins, 
the effect of certain PXR activators is to repress the inflammatory response. 
Although it has been known for 40 years now that the PXR activator rifampicin 
inhibits immunological responses in liver cells, the mechanisms remain poorly 
understood. Previous results indicate that modification of PXR by small 
ubiquitin-related modifier (SUMO) likely contributes to this phenomenon. We 
hypothesize that PXR is SUMOylated to transrepress the inflammatory response 
genes in liver. Here, this thesis examines PXR SUMOylation/de-SUMOylation 
reaction mechanisms using in vitro and cell-based methods.  Bacterial 
expression and purification systems were used in conjunction with in vitro 
SUMOylation reactions to further analyze PXR SUMOylation by both SUMO-1 
and SUMO-3. The data reveal that the E3 SUMO-protein ligase protein inhibitor 
of activated STAT protein y (PIASy) potentiated SUMOylation of the PXR 
ligand binding domain (PXR-LBD) in vitro.  Cell-based methods were used to 
characterize the de-SUMOylation of PXR using expression vectors encoding six 
different sentrin protease (SENP) enzymes including SENP1, SENP2, SENP3, 
SENP5, SENP6, and SENP7.  Both SENP1 and SENP2 effectively 
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de-conjugated both SUMO-1 and SUMO-3 from PXR, whereas SENP6 
inhibited the formation of SUMO-3 chains on PXR.  Collectively, the data 
suggest that (1) PXR can serve as a substrate for either SUMO-1 or SUMO-3 in 
vitro and in cell-based assays, (2) both SENP1 and SENP2 are able to remove 
SUMO moieties in a cellular environment, and (3) that SENP6 removes or 
prevents the formation of SUMO-chains on PXR. Taken together, the work 
presented in this thesis contributes to understanding the interface between PXR 
activators, the SUMOylation pathway and PXR activity. Future efforts should 
seek to determine the extent to which the biochemical mechanisms described 
here function in human liver and intestine in patients undergoing therapy with 
PXR activators. These studies are deemed critical for safe pharmacological 
strategies for addressing adverse drug reactions and provide a new paradigm for 
exploring novel approaches to repress inflammatory signaling in liver and 
intestine.  
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Introduction 
1. General Introduction to NR Superfamily 
Historically, the lipophilic hormones, including steroids, retinoids and 
thyroids, are known as regulators of differential control of gene expression in 
development, cell differentiation, metamorphosis and organ physiology (1). The 
steroid receptors were first identified in the mid-1980s with the help of purified 
hormones and antibodies (2-5). The cloning of cDNAs encoding the 
glucocorticoid (GR) and estrogen (ER) receptors has led to the discovery of the 
receptors for numerous fat-soluble hormones (6). During this time, the receptors 
were found to exhibit high sequence similarity; hence the concept of the 
existence of a NR superfamily emerged. By 1990, there were a total of 15 
members in the NR superfamily. To date, there are 48 functional NR family 
members encoded in the human genome. A group of receptors, called orphan 
receptors, were first found in metazoan species based on low stringency 
hybridization screening technique and PCR-based cloning strategies (1). 
However, at the time of their cloning, their physiological ligands were not 
known.  Effort to identify the physiological ligands of orphan receptors enabled 
receptor “adoption” after their ligands were found. This search has led to the 
discovery of novel metabolic gene regulation networks and endocrine signaling 
pathways in animal biology (7). Members of adopted NRs include receptors for 
fatty acids (peroxisome proliferator-activated receptors (PPARs)), bile acids 
(farnesoid x receptor (FXR)), oxysterols (liver x receptors (LXRs)) and 
xenobiotics (PXR).  
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All members of NR superfamily share several conserved domains that are 
essential for receptor function. At the N-terminal region of NRs, the activation 
function 1 (AF-1) domain can act to activate transcription of target genes in a 
ligand-independent manner (8). It contains consensus phosphorylation sites and 
is responsive to several kinase signaling pathways (9). The DNA binding domain 
(DBD) contains two  helices and two zinc fingers that provide DNA binding 
specificity. The DBD of NRs binds to well-defined hormone response elements 
(HREs), and also imparts NR dimerization characteristics (10). Most NRs 
function as dimers, while some NRs are active as monomers, such as 
steroidogenic factor 1 (SF-1) (11). Most steroid NRs function as homodimers 
and bind to DNA binding sites organized as inverted repeats (12). Several 
important liver-enriched NRs function as heterodimers with the retinoid X 
receptor (RXR) including LXR, FXR, constitutive androgen receptor (CAR) and 
PXR. The C-terminal region of NRs includes the activation function-2 (AF-2) 
domain and the ligand binding domain (LBD). The LBD is connected to DBD 
by a flexible hinge domain which contains a nuclear localization signal (NLS). 
The AF-2 domain is predicted to undergo a conformational change upon ligand 
binding, and also serves as a binding surface for co-activator proteins necessary 
for transactivation (13). (Figure 1)  
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Figure 1. Domain Structures of Nuclear Receptors. Most members of the NR 
superfamily have a common domain structure consisting of an N-terminal AF-1, 
a central DBD and a C-terminal LBD.  
2. NR Co-regulators 
Expression cloning and functional characterization of a larger number of 
proteins which interact with NRs in either a ligand-dependent or independent 
manner have gained increasing attention (14). NR co-regulator proteins are 
critical components of large multi-protein complexes, including co-activators 
and co-repressors, which do not bind to DNA directly but have pivotal roles in 
regulation of target gene expression (15). Generally, genes are maintained in an 
off-state by recruitment of co-repressor complexes. Such complexes include 
nuclear receptor corepressor (NCoR) and silencing mediator for retinoic acid 
and thyroid hormone receptors (SMRT) (16). NCoR and SMRT do not harbor 
intrinsic enzymatic activity; instead they serve as the scaffold to interact with 
other protein co-factors which contain intrinsic histone deactylase (HDAC) 
activity (17). Non-liganded NRs recruit HADCs to remove acetyl groups from 
histone tails and induce chromatin compaction that prevents association of basal 
transcriptional machinery with enhancer regions of genes (18). This leads to 
NRs-mediated active repression of target gene expression in the non-liganded 
condition.  
The binding of ligand to NRs results in the dissociation of the co-repressor 
complexes and subsequent recruitment of co-activator proteins to initiate target 
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gene transcription, which is called transactivation (19). Most co-activators 
proteins interact with NRs in a ligand-dependent manner through the C-terminal 
AF-2 domain via an -LXXLL- motif, where L is leucine and X is any amino acid 
(20). The NR-associated co-activator multi-protein complexes contain both 
intrinsic and extrinsic histone acetyltransferase (HAT) activity (21), a chromatin 
remodeling function (22), as well as mRNA elongation and splicing activity (23).  
Steroid receptor co-activator (SRC) proteins are co-activators for PXR 
transactivation. The SRC family contains intrinsic HAT activity and it also 
interacts with another HAT and p300/CBP-associated factor (PCAF) to form the 
co-activator complexes (24). 
Besides ligand-induced co-regulator exchange, the activation of cell 
signaling cascades and phosphorylation events by protein kinase directly 
regulate the strength of interaction between the NRs and co-regulator 
multi-protein complexes (25-27). Understanding the role of cell signaling 
pathways that modulate NRs protein-protein interactions, DNA binding and 
transcriptional activity is necessary for functional implication of these signaling 
events.   
Based on the enzymatic functions of co-regulator proteins, NRs can likely 
regulate gene transcription by different mechanisms, including ligand-dependent 
transcriptional activation, ligand-independent active repression and 
transrepression (28). Several important questions regarding the molecular 
mechanisms of NRs-mediated gene transrepression will be addressed in the next 
few sections of this thesis.  
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3. Pregnane X Receptor (PXR) 
The mouse pregnane x receptor (PXR, NR1I2) was first identified in 1998 
based on its sequence homology to the LBD of a number of NRs in the motif 
search of sequence tag databases (7).   The receptor was named as PXR based 
on its activation by several synthetic pregnanes (7). The tissue-specific 
expression profiles of PXR were examined and characterized. Northern blot 
analysis showed that abundant level of PXR mRNA is observed in liver and at a 
moderate level in the intestine (29). Since the promoter which drives Pxr gene 
expression has not been well characterized, the molecular mechanisms 
underlying this tissue-specific expression of PXR are currently unknown. 
Previous studies suggest that the Pxr gene might be regulated by liver-enriched 
transcription factor hepatic nuclear factor 4  (HNF-4 and/or steroid 
hormones (31,32).  
PXR functions as a heterodimer with RXR and is activated by numerous 
prescription drugs, xenobiotics, steroids and toxic bile acids (33). In fact, 
elucidation of the crystal structure of the LBD of human PXR revealed that it has 
a relatively large and spherical ligand-binding pocket which allows it to interact 
with a vast variety of hydrophobic chemicals (33,34). However, marked 
differences in the activation profiles of PXR across species exist. The 
rodent-specific PXR ligand pregnenalone 16-carbonitrile (PCN) and several 
other naturally occurring 21-carbon steroids have little or no effect on PXR 
activity in human and rabbit hepatocytes. On the other hand, rifampicin (Rif), 
the human PXR activator, fails to induce the transcription of Cyp3a11 which is 
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the prototypical PXR-target gene in mouse and rat hepatocytes (29,35). The 
recent availability of high-resolution PXR LBD crystal structure has provided 
critical clues that elucidate the basis for the observed species-specific differences 
in PXR activation profiles (33,36,37). The comparison of the residues in the 
LBD pocket of PXR across species showed that only four polar residues are 
different between mouse and human PXR. Recent targeted site-directed 
mutagenesis studies of the four key residues effectively humanized mouse PXR 
and conferred mouse PXR a human-like response in a cellular environment 
(33,38).  
Upon biding with the ligand, the PXR-RXR heterodimer binds to the PXR 
response elements (PXREs) that are located in the CYP promoter region and 
activates CYP gene expression in liver (39). In addition, PXR regulates the 
expression of numerous other genes involved in the metabolism and transport of 
xenobiotic compound, including phase I oxidation enzymes carboxylesterases 
(CESs) (40), phase II conjugation enzymes glutathione S-transferases (GSTs) 
(41) and sulfotransferases (SULTs) (42), and the genes encoding phase III drug 
transporters organic anion transporting polypeptide 2 (Oatp2) (43) and 
multi-drug resistance-associated protein family (Mrp2 and Mrp3) (44) in the 
entero-hepatic system. 
4. Physiological Functions of PXR 
4.1 PXR is a Positive Regulator of Genes Encoding Enzymes that 
Participate in Biotransformation 
4.1.1 Xenobiotic Responses 
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PXR is activated by a myriad of lipophilic compounds, including certain 
natural and synthetic steroids, bile acids, and a variety of drugs (7). It is a 
master-regulator of drug-inducible CYP3A gene expression in drug metabolism 
and detoxification and elimination of xeno-chemicals prevalent in the 
environment (45).  
When specific xenobiotic compounds enter the liver, they activate PXR and 
up-regulate gene transcription for gene products responsible for xenobiotic 
biotransformation reactions. The catalytic action of the CYP3A family of 
enzymes, as well as other drug metabolizing enzymes (DMEs) in the liver, 
increases the water solubility of substrates mainly through oxidative metabolic 
reactions that result in the addition of hydrophilic groups to polar substrates. 
Additional PXR-target genes encode key drug transporter proteins that promote 
the uptake and excretion of xenobiotics to urine and bile. In this manner, PXR 
activation represents an adaptive response to protect the body against toxic 
assaults through accelerating the clearance of xenobiotics by inducing drug 
metabolism and drug transport (46).  
PXR activation and up-regulation of CYP3A genes also form the molecular 
basis for an important class of drug-drug, herb-drug, and food-drug interactions 
in patients on combination therapy (47). Many of the xenobiotics that induce 
PXR are widely used prescription drugs, such as the antibiotic Rif (29), the 
glucocorticoid dexamethasone (32), and the antimycotic clotrimazole (48). The 
human CYP3A4 enzyme is involved in the oxidative metabolism of 
approximately 50-60% of all clinically prescribed drugs (49). Therefore, 
PXR-mediated activation of high levels of CYP3A in the liver would be 
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expected to interfere with the pharmacokinetics to increase metabolism of other 
co-administered drugs which are CYP3A substrates. Since many patients are 
likely to take more than one medication simultaneously (50), this phenomenon 
can be a serious problem during combination therapy, especially in patients with 
underlying co-morbidities that alter drug metabolic pathways. The major clinical 
consequence is therapeutic failure because of the undesirable lowering of the 
plasma level of the affected drug to non-therapeutic range (51,52).  
The active compounds in natural herbal remedies contribute to inadvertent 
activation of PXR and thereby represent the molecular basis for a significant 
portion of herb-drug interactions (53-55). An example is the compound 
hyperforin, the active component of St John’s wort (Hypericum perforatum L.), 
which binds to PXR with high affinity and activates CYP gene expression (56,57) 
to enhance the oxidative metabolism of various prescription drugs, including 
combination oral contraceptives, cyclosporin, and indinavir (58-63).  
Food constituents also have the ability to activate PXR and are responsible 
for food-drug interactions (55,64). Food consisting of phytochemical mixtures, 
such as fruits, vegetables (65), beverages, and teas possess the ability to alter the 
activity of CYP3A through PXR activation (66), and modulate the metabolism 
of more than 50% of clinical pharmaceuticals by CYP3A (67).  
Taken together, PXR activation in the liver and intestine could lead to 
undesirable life-threatening drug-drug and supplement-drug interactions in 
patients using combination therapy. Therefore, the drug development industry is 
employing high throughput in vitro and in vivo PXR activation and binding 
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assays to test novel drug candidates for their ability to induce CYP3A gene 
expression (68). In order to reduce adverse drug effect, the ideal drug candidate 
should be neutral with respect to their effects on CYP gene expression (69). The 
compounds might be removed from the drug development process if they are 
potent PXR activators (34). For example, the anti-diabetic drug troglitazone, a 
potent PPAR activator (70), was withdrawn from the market due to 
hepatotoxicity (71). It activates PXR at the therapeutic dose (35) and its 
metabolites quinones catalyzed by CYP 2C8 and CYP3A4 are active 
intermediates in drug-induced hepatic toxicities (72-74). In the contrast, the 
related drugs rosiglitazone and pioglitazone, which are potent PPAR activators 
and remedies for diabetes (75), do not activate PXR and form reactive quinones 
metabolites (76). Thus they have not shown any evidence of hepatotoxicity in 
patients (72,77,78). 
4.1.2 PXR Regulates Bile Acid Homeostasis 
In addition to a myriad of foreign chemicals, animals confront numerous 
endogenous toxicants whose efficient detoxification is important to animal 
survival (79).  
Bile acids are synthesized from cholesterol in the liver and are among the 
first natural products isolated in pure form (80). They are present in dried 
extracts of bear bile, which have been used for their medicinal properties by 
Asian cultures for thousands of years (81,82). Bile acid synthesis provides a 
direct means of converting a cholesterol molecule, which is the insoluble and 
hydrophobic membrane constituent, to a bile acid molecule that, when ionized, is 
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the membrane-dissolving, water-soluble and readily-excreted detergent (83,84). 
The physiological roles of bile acids involve elimination of cholesterol, 
absorption of dietary lipids, hepatic bile formation and regulation of hepatic 
cholesterol synthesis (85).  
The primary bile acids, including cholic acid and chenodeoxycholic acid, 
are synthesized in the liver through cholesterol oxidative catabolism (86). The 
secondary bile acids deoxycholic acid and lithocholic acid (LCA) are formed in 
the intestine from primary bile acids (87). The synthesis of a full complement of 
bile acids is a complex process, requiring 17 enzymes (84,88) and the multi-step 
conversion of cholesterol to bile acids confers the detergent-like properties to the 
bile acids that are essential for their physiological functions (89).  
The expression of selected enzymes in the bile acids synthesis pathway is 
tightly regulated by NRs and other transcription factors, which ensure a constant 
supply of bile acids and the maintenance of hepatic cholesterol catabolism (83). 
While FXR (NR1H4) and LXR (NR1H3) play a fundamental role in regulating 
bile acid and cholesterol levels in the liver (79,90), PXR is also involved in the 
regulation of biosynthesis, transport and metabolism of bile acids that are 
extremely toxic at excessive concentrations occurring during 
hypercholesterolemia and cholestasis (79,91).  
The rate limiting step in bile acid formation is the 7-hydroxylation of 
cholesterol by CYP7A1 enzyme (92). PCN treatment negatively regulates 
Cyp7a1 expression in mice, which suggests that PXR activation blocks bile acids 
synthesis (93). Among the genes that are up-regulated by PCN treatment are 
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Oatp2 and CYP3a11 (43,45). The CYP3A11 enzyme catalyzes the 
hydroxylation of bile acids, and OatP2 transports bile acids across the sinusoidal 
and canalicular membranes of hepatocytes (84) (Figure 2).  
Since PXR regulates key enzymes in bile acid PXR biosynthesis, transport 
and metabolism, it provides a fundamental molecular basis for Rif treatment in 
patients suffering from chronic cholestatic liver disease (43,94). Cholestasis, a 
pathogenic state characterized by cessation or impairment of bile flow and the 
accumulation of toxins normally excreted in bile, can cause nutritional 
imbalance and irreversible liver damage (95). LCA is a highly toxic secondary 
bile acid that causes cholestasis when accumulated in the body (43,79). The 
harmful effects of LCA and other bile acids are attenuated by two mechanisms, 
namely hydroxylation and conjugation, for elimination and detoxification of bile 
acids (96). LCA at the pathophysiological level binds to PXR, whose activation 
down-regulates Cyp7a1 to block bile acids synthesis, accelerates metabolism 
catalyzed by CYP3A and promotes uptake of bile acids from the blood by 
induction of OatP2 (43,97). These reactions make LCA more hydrophilic and 
facilitate the excretion of bile acids in the urine or feces. Therefore, PXR is 
critical as an endogenous bile acid receptor and regulates bile acid homeostasis 
in bile acid elimination and detoxification. Potent PXR ligands may be 
efficacious in the treatment of cholestasis and other hepatic diseases (98). 
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Figure 2 
 
Figure 2. Regulation of Bile Acid Homeostasis by PXR. PXR is activated by 
bile acids and regulates genes involved in the biosynthesis, transport and 
metabolism of cholesterol and bile acids. Genes up-regulated by PXR are 
indicated by the green arrows. Genes down-regulated by PXR are indicated by 
the red line. PXRE, PXR response element; MRP2, Multidrug resistance 
associated protein 2. 
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4.2 Negative Physiological Functions of PXR 
Besides the involvement in the regulation of xenobiotics/endobiotics 
metabolism and transport, PXR also governs ligand-dependent repressive effects 
upon gluconeogenesis, lipid-oxidation and subsequent ketogenesis, and the 
inflammatory response, likely through crosstalk with other signaling pathways 
controlling these essential biological functions.  
4.2.1 Glucose Homeostasis 
Hepatic glucose production is tightly regulated by insulin and glucagon 
signaling pathways which play a major role in animal survival during fasting and 
starvation. Genes that are involved in gluconeogenesis include 
glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase 
(Pepck), which are the rate-limiting enzymes that control the serum level of 
glucose (99). In the liver, gluconeogenesis is positively regulated by glucagon, 
cAMP and glucocorticoid, which increase glucose production by induction the 
transcription of G6Pase and Pepck, whereas insulin and glucose suppress the 
expression of these genes (100).  
Ligand-mediated activation of PXR interferes with the regulatory gene 
networks that control glucose homeostasis. For example, PCN decreases blood 
glucose levels in fasting wild-type mice but not in PXR-null mice (101). Pepck1 
and G6Pase genes are reduced in the transgenic mice expressing constitutively 
activated PXR in the liver and intestine (102). These observations are in 
consistent with the result that PXR activation down-regulates the transcriptional 
activity of FoxO1, a positive regulator of gluconeogenic genes (103).  
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FoxO1 is a member of the fork head family of transcription factors which 
are characterized by the fork head domain (104). The de-phosphorylated form of 
FoxO1 positively regulates the transcription of genes involved in 
gluconeogenesis. Insulin exerts a repressive action on FoxO1 by activating the 
phosphatidylinostiol-3-kinase (PI3K)-Akt pathway to increase phosphorylation 
of FoxO1 (105). The phosphorylated FoxO1 protein is then sequestered in the 
cytoplasm to remain transcriptionally inactive (106). Additional studies reveal 
crosstalk between FoxO1 and PXR (103,107). Ligand-dependent activation of 
PXR prevents FoxO1 binding to its insulin response sequences in target genes 
such as G6Pase and Pepck, thereby inactivating FoxO1 transcriptional activity 
(100,103).  
Glucose production is also mediated by liver-enriched hepatic nuclear 
factor 4α (HNF4α) transactivation through its recruitment of co-activator protein, 
PPARγ coactivator-1α (PGC-1α) (108). Ligand-activated PXR interferes with 
the interaction of HNF4 with PGC-1α to suppress HNF4α transactivation (109). 
This represents another mechanism by which PXR ligand-dependent activation 
might suppress hepatic gluconeogenesis.  
Finally, it has been proposed that PXR could interfere with the 
cAMP-response element binding protein (CREB) signaling pathway (101). 
CREB is phosphorylated by cAMP-dependent protein kinase (PKA) in response 
to glucagon secretion during fasting state. CREB binds to cAMP-responsive 
elements (CRE) to activate the transcription of genes encoding gluconeogenic 
enzymes G6Pase and PEPCK1 (110). PXR binds to CREB to prevent the 
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interaction between CREB and CRE on the promoter regions of these genes, 
thus repressing CREB-mediated gene activation programs.  
    In this manner, the crosstalk between the signaling pathways that control 
glucose homeostasis and drug metabolism demonstrate that PXR directly 
interacts with other transcription factors and accessory proteins, such as FOXO1, 
CREB, and PGC-1α, all of which are critical for efficient gluconeogenic gene 
transcriptional regulatory circuits (111).  
4.2.2 Lipid Metabolism 
As described above, liver is the major site for drug metabolism. Liver is 
also the organ that metabolizes lipids to produce energy in the form of ATP from 
fat during the fasting and starvation response. Hepatic lipid homeostasis involves 
balanced lipid synthesis (lipogenesis), fatty acid catabolism (β-oxidation), lipid 
uptake and secretion (102). When blood glucose is low, liver provides the energy 
sources in the form of ketone bodies (acetoacetate and 3-hydroxybutylate) to the 
extra-hepatic tissues via β-oxidation of fat and ketogenesis from the Krebs cycle 
(112). Recent clinical observations reveal that PXR activation affects lipid 
metabolism in patients treated with PXR activators. For example, treatment with 
the antibiotic and PXR activator Rif induces hepatic steatosis in tuberculosis 
patients (113). Transgenic mice expressing constitutively active PXR exhibit 
marked triglyceride accumulation (114).  
The role of PXR in the development of hepatic steatosis is linked to 
expression of transcription factors and enzymes that function in lipogenesis, 
such as stearoyl-CoA desaturase 1 (SCD1), a key enzyme in the synthesis of 
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unsaturated fatty acids (115). Insulin increases the transcription of SCD1 by 
activating the lipogenic transcription factor sterol regulatory element-binding 
protein (SREBP) (116). But, PXR activation-induced hepatic lipid accumulation 
in transgenic mice is independent of SREBP, and is linked to increased 
expression of the free fatty acid transporter Cd36 and accessory lipogenic 
enzymes such as SCD1 and long-chain free fatty acid elongase (102,117). Cd36 
has been shown to be regulated by oxidized low density lipoprotein and long 
chain fatty acids (118). Cd36 is a previously indentified PPARγ target gene 
(119), and this study showed that PXR may increase the expression of Cd36 by 
directly binding to the Cd36 promoter. In fact, there is a direct repeat spaced by 
three nucleotides spacer (DR-3) PXRE in the mouse Cd36 promoter, which 
suggests that Cd36 serves as a direct transcription target of PXR and it can be 
activated by both PXR and PPARγ to regulate lipid homeostasis (102).  
PXR activation also provokes suppression of several genes whose gene 
products function in β-oxidation. Treatment of mice with PCN inhibits lipid 
oxidation by down-regulating the expression of carnitine palmitoyltransferase 1α 
(CPT1α) and mitochondrial 3-hydroxy-3-methylglutarate-CoA synthase 2 
(HMGCS2), two key enzymes involved in β-oxidation and ketogenesis. 
Importantly, PXR-mediated down-regulation of these two genes is present in 
wide type but not PXR-null mice. It has been shown that activated PXR can 
physically interact with Forkhead box A2 (FoxA2) and prevent FoxA2 binding 
to the Cpt1a and Hmgcs2 gene promoters, thereby rendering FoxA2 
transcriptionally inactive.  
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In addition, ligand-activated PXR interferes with HNF4α by targeting the 
PGC-1α co-activator protein to function in lipid homeostasis. HNF4α and 
PGC-1α jointly regulate the expression of CPT1α (120).  Besides the 
interaction with FoxA2, PXR interferes with HNF4α in the regulation of CPT1α 
as well. Therefore, PGC-1α represents a coordinate point of crosstalk between 
PXR and other signaling pathways (100). 
4.2.3 Inflammatory Response  
    Exposure to xenobiotic chemicals can impair immune function. Treatment 
of patients with Rif suppresses humoral and cellular immune responses in liver 
cells (121). Rif’s immunosuppressive role has been well described in humans 
since 1970s (122-125). It had been suggested that the immunosuppressive effects 
were mediated by Rif acting as a ligand and activator for the GR (126). But the 
result was not supported by other groups who showed that Rif is not a 
biologically significant activator for GR (126,127).  
After PXR (NR1I2) was characterized and cloned in 1998 (29), Rif is 
identified as a potent ligand and activator of human PXR (7). Considering that 
human PXR activates CYP3A, these findings help to explain the prior reported 
studies that CYP3A is the major CYP gene induced by Rif in human primary 
hepatocytes (128). But the mechanism through which Rif exerts 
immunosuppressive effects remains unknown. Hepatic P450 activity is 
down-regulated by various infectious and inflammatory stimuli, primarily due to 
inhibition of P450 gene transcription (129). Since PXR is a mater-regulator of 
CYP3A gene, it has been hypothesized that inflammation could suppress PXR 
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transcriptional activity. Recent reports have described mutually repressive and 
negative crosstalk between the PXR and NF-κB signaling pathway, thus 
providing a potential molecular mechanism that links xenobiotic response and 
inflammation (130-132) (Figure 3).  
There are five members in the NF-κB family, namely p65 or Rel A, Rel B, 
c-Rel, p50, and p52 (133). NF-κB is a key regulator of inflammation and the 
innate and adaptive immune responses. Under basal condition, p65 is normally 
sequestered in the cytoplasm by the inhibitory protein inhibitor of NF-κB (IκB).  
(133). In response to activation signals, such as inflammatory stimuli, 
pro-inflammatory cytokines, reactive oxygen species and viral products, 
downstream signaling events induce phosphorylation, ubiquitination, and 
proteosome-dependent degradation of IκB and release NF-κB to translocate to 
the nucleus where it regulates the expression of inflammatory genes. (134)  
Activation of PXR by Rif suppresses the expression of typical NF-κB target 
genes, such as cyclooxygenase 2 (COX-2), tumor necrosis factor alpha (TNF), 
intercellular adhesion molecule 1 (ICAM-1 or CD54), and several interleukins. 
(130) Conversely, NF-κB target gene expression is elevated in hepatocytes 
derived from the PXR-null mice compared to that from the wild type animals 
(132). The PXR-null mice also exhibit a prominent and increased small bowel 
inflammatory infiltrate. (130) These observations indicate that PXR is involved 
in suppressing the NF-κB-regulated gene expression and deregulation of PXR 
expression or activity may make the gastrointestinal tract susceptible to 
inflammatory injuries (100). 
19 
In turn, inflammatory stimuli decrease xenobiotic metabolism capacity in 
human and experimental animals. One example is the bacterial toxin 
lipopolysaccharide (LPS), which activates NF-κB through a sequential TLR4 
intracellular signaling cascade.  (135). Another example is the inflammatory 
cytokine TNFα. It binds to its receptor (TNFR) and recruits TNFR1-associated 
death domain protein (TRADD), TNF receptor-associated factor protein 
(TRAF2) and other signaling transducer proteins, which lead to translocation of 
NF-κB into the nucleus (136). LPS and TNFα-induced NF-κB activation have 
been shown to suppress CYP3a4 gene expression. NF-κB p65 subunit directly 
interacts with the DBD of RXR and inhibits its binding to the consensus DNA 
sequences. Because PXR functions as a heterodimer with RXR the 
transactivation by the PXR-RXR complex is down-regulated in response to 
NF-κB signaling pathway (131). 
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Figure 3  
 
 
 
Figure 3. Mutual transrepression between PXR and NF-κB signaling 
pathway. The PXR and NF-κB mutual suppression may link xenobiotic 
response and inflammation in the hepato-intestinal axis. COX-2, 
Cyclooxygenase 2; ICAM, intercellular adhesion molecule; LPS, 
lipopolysaccharide; NF-κB, nuclear factor kappa B; PXR, pregnane X receptor; 
PXRE, PXR response element; TNF, tumor necrosis factor. 
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5. Mechanisms of PXR Transcription Regulation 
Considering the distinct regulatory roles of PXR in several physiological 
conditions, we next discuss its different mechanisms of transcription regulation, 
including both transactivation and transrepression.  
The most prevalent activation of CYP3A by PXR is mediated by a linear 
series of events. It was previously believed that human PXR resided exclusively 
to the nucleus even in the absence of ligand (137). However, other studies have 
detected cytoplasmic localization of PXR and ligand-dependent translocation of 
PXR from the cytoplasm to the nucleus after binding with a ligand (138,139). 
Further evidences demonstrate the interaction of PXR with heat shock protein 90 
(HSP90) and cytoplasmic CAR retention protein (CCRP) in the cytoplasm of 
liver cells (139). Upon ligand binding, PXR dissociates from the CCRP-HSP90 
complex and translocates to the nucleus where it binds as a heterodimer with 
RXR to the DNA response element composed of two copies of the consensus 
NR binding motif AG (G/T) TCA (34,140). The response elements are 
organized as direct repeats with 3 to 5 nucleotides separating the DBD binding 
sites (DR-3, DR-4, and DR-5 elements), as well as everted repeats separated by 
6 or 8 nucleotides (ER-6 and ER-8 elements) (29).  
The full functional activity of PXR is linked to the recruitment of 
co-regulator proteins that have pronounced effect on gene expression through 
protein-protein interaction instead of binding to DNA directly. Generally, 
non-liganded PXR interacts with co-repressor complexes including NCoR/ 
SMRT and HDACs (141,142). The co-repressor complexes exert inhibitory 
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effect on transcriptional activity and maintain chromatin structure in the compact 
state, thus reducing the accessibility of enhancer region of target gene to the 
necessary basal transcriptional machinery. For example, un-liganded PXR 
interacts with SMRT to repress the basal transcription of CYP3A gene which is 
reversed by PXR ligand paclitaxel (143). In the presence of ligand, the 
C-terminal AF-2 domain undergoes a conformational change that favors binding 
with co-activator proteins via the –LXXLL- motif. The co-repressor protein 
complexes are dissociated and multi-protein co-activator complexes including 
HAT are recruited subsequently (Figure 4). In this process, TBL1/TBLR1, the 
component of NCoR co-repressor complexes (144), serves as the NR 
co-repressor/co-activator exchange factor (N-CoEx) (145). It functions as the 
adaptor factor to recruit the ubiquitin conjugating/19S proteasome complex that 
targets the co-repressor complexes for degradation after ligand binding (145).  
In the contrast to transcriptional activation, which usually involves the 
binding of PXR to its HRE in the promoter region of CYP3A gene, the 
inhibition of NF-B activity does not require PXR to directly bind to typical 
response elements. Transrepression is widely involved in negative regulation of 
gene expression. Previous results suggest that PXR may negatively regulate 
inflammatory response through protein-protein interaction in a 
SUMOylation-dependent pathway. But this SUMOylation-dependent 
transrepression mechanism remains to be further identified.  
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Figure 4 
 
 
 
 
Figure 4. PXR activity is regulated by different co-factor interactions. PXR 
interacts with co-repressor complexes which recruits HDACs. This inhibits 
transcriptional activity through promoting chromatin compaction and reducing 
accessibility of genes to basal transcriptional machinery. Ligand binding induces 
a conformational change and dissociates the co-repressor complexes. The 
co-activator complexes with HAT activity are recruited to promote histone 
acetylation and enhance gene transcription.  
There are several models of NRs-mediated transrepression: first, NRs 
regulate key components in the NF-B and AP-1 signal-transduction pathways 
(146-148); second, NRs compete with NF-B and AP1 for limiting amount of 
co-activators (149,150); third, NRs alter NF-B and AP1 co-regulator complex 
composition (151,152); and last, NRs modify basal transcription machinery 
(153,154).  
Several recent reports indicate a general molecular strategy for 
SUMOylation of a subset of NRs that transrepress immunity in a signal and 
gene-dependent manner. For example, a SUMOylation-dependent pathway has 
been identified in which PPAR mediates the transrepression of inflammatory 
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response genes in mouse macrophages.  Ligand induced SUMO modification 
of PPAR- and then the SUMOylated ligand-bound PPAR- inhibits gene 
transcription by preventing signal-dependent recruitment of ubiquitin-19S 
proteasome complex required for NCoR clearance from inflammatory gene 
promoter/enhancer region. Subsequent research in LXRs indicates that 
SUMOylation is required for the repression of interferon- (IFN-) response 
genes in brain astrocytes. SUMOylated LXRs form complexes with SUMO E3 
ligases and signal transducer and activator of transcription 1 (STAT1), thus 
preventing STAT1 binding to DNA in response to IFN- stimulation.  
Importantly, previous results from our lab have demonstrated that PXR is 
SUMOylated in response to inflammatory stimulation and represses the NF-B 
target gene expression (132). These findings raise our interest in further studying 
PXR SUMOylation/de-SUMOylation mechanisms to unravel the importance of 
this post-translational modification in inflammatory response.  
6. PXR SUMOylation 
The SUMOylation pathway results in the covalent attachment of SUMO to 
substrate proteins. SUMO is a small polypeptide, ~10kD in size. The first 
SUMO protein found was the Saccharomyces cerevisiae suppressor of mif two 3 
homolog 1 (SMT3) (155). Based on two-hybrid interaction screening and 
cloning, SUMO proteins have been found to be present in plant, yeast, fly and 
other species. Within mouse and human, there are four types of SUMO proteins, 
named as SUMO-1, -2, -3 and -4. However the functionality of SUMO-4 remains 
currently unclear, so that SUMO-4 will not be discussed in this thesis. SUMO-1, 
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-2 and -3 are all highly conserved during the evolutionary process (156). 
SUMO-2 and SUMO-3 share 97% sequence identity so that they are always 
termed as SUMO-2/3, while SUMO-1 shares only 50% sequence identity with 
SUMO2/3 (Figure 5A).  
The SUMO proteins have C-terminal extension of 2-11 amino acids. They 
are expressed in the immature forms initially and need C-terminal extension 
removed by SUMO-specific proteases (SENPs) to expose the invariant 
glycine-glycine motif for maturation. After the maturation process, the mature 
forms could enter the three-step SUMOylation pathway. The first step is the 
activation of the mature SUMO protein by the SUMO-specific heterodimeric E1 
activating enzyme, AOS1-UBA2 complex, which has both adenylation and 
thioesterifiation functions (157,158). The ATP-dependent reaction forms a 
thioester bond between the C-terminal carboxyl group of glycine and a catalytic 
cysteine residue in E1 (159). The second step involves transferring the SUMO 
protein from the E1 activating enzyme to the E2 conjugating enzyme, Ubc9, 
which leads to a new thioester bond between the C-terminal carboxyl group of 
SUMO and a catalytic cysteine residue in E2 (160). Efficient modification by 
SUMO protein, especially in vivo, further requires the action of specific SUMO 
E3 ligases, which catalyze the shift of SUMO to the target and the formation of 
an isopeptide bond between the glycine residue of SUMO and the lysine residue 
of the target (161) (Figure 5B).  
Several E3 ligases have been identified. The first E3 ligase found in yeast 
was Siz1(162) and the mammalian PIAS proteins have been found to increase 
the rate of SUMO conjugation in vivo subsequently (163). There are at least four 
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subtypes of PIAS proteins, namely 1, 3, x and y (164). The PIAS family has a 
central RING-FINGER-like motif that binds to targets and Ubc9 directly and 
interacts with SUMO through a non-covalent SUMO-interaction/binding motif 
(SIM) (165). The nucleoporin Ran-binding protein 2 (RanBP2) represents 
another type of E3 ligase (166). It increases the rate by positioning the thioester 
bond between SUMO and Ubc9 to an optimal orientation for attack by substrate 
(167) instead of directly interacting with substrate. In addition, the human 
Polycomb group member Pc2 (168) and histone deacetylase HDAC4 (169) have 
also been recently found to function as E3 ligases.  
The acceptor sites on SUMO targets follow a consensus sequence. It is 
shown to be -K-x-D/E, where  is a hydrophobic amino acid, K is the lysine 
residue, x is any amino acid, and D/E is an acidic residue. Many proteins carry 
the consensus SUMOylation sequence, even the SUMO proteins themselves. 
The N-terminal extension of SUMO-2/3 has the SUMO acceptor site and is 
targeted by E1, E2 and E3 to form polymeric chains. This feature is not shared 
by SUMO1, since it does not contain the consensus SUMOylation sequence on 
itself. The distinct chain formation capacity may suggest in part different roles 
and functional consequences of modification by SUMO-2/3 versus SUMO-1 
which will be discussed in the following sections. 
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Figure 5 
A) 
 
 
 
B) 
 
 
 
 
 
 
 
 
Figure 5. PXR Reversible SUMOylation Pathway. A) The sequences of 
human SUMO-1, -2, and -3 are compared. Similarities are indicated by red 
asterisk. The consensus SUMOylation site (K11) on SUMO-2/3 is shown with 
green box. Sentrin proteases cut C-terminal extensions to expose the 
glycine-glycine motif. B) The mature SUMO  protein  is  incorporated  into  
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its  specific  substrate  by  a  cascade  of enzymes termed as E1, E2,  
and E3  to  produce SUMO-modified  substrates  in  a signal-dependent 
manner.  Specific sentrin protease enzymes then cleave the SUMO moiety from 
substrates and allow the SUMO moiety to recycle. 
The SUMOylation pathway is highly dynamic and reversible. 
De-SUMOylation is potentially catalyzed by SENPs, which belong to the family 
of cysteine proteases with conserved C-terminal catalytic domains. Mammalian 
genomes encode up to seven SENPs, designated SENP1-3 and SENP 5-8 (Figure 
6A). Although SENP8 shares the conserved catalytic domain, it has been shown 
to be a NEDD8-specific protease and lack the ability to process or de-conjugate 
SUMO substrates (170). Other six SENPs contain both endopeptidase and 
isopeptidase activity for de-conjugating SUMO from substrates (Figure 6B).  
Based on their functional activities and preferences towards targets, 
mammalian SENPs can be classified into three groups. SENP1 and SENP2 are 
able to target all SUMO isoforms and function both in their processing and 
de-conjugation pathways. SENP3 and SENP5 regulate the modification of 
monomeric SUMO-2/3 and to a less extent SUMO-1 conjugates. SENP6 and 
SENP7 also regulate preferentially on SUMO-2/3. Neither SENP6 nor SENP7 
act on maturation of SUMO protein precursors and they show no activity in the 
de-conjugation of monomeric SUMO-2/3 from substrates. Rather, the main role 
of SENP6 and SENP7 is to de-conjugate poly-SUMO-2/3 chains.  SENPs can 
also be distinguished based on their different sub-cellular localizations. SENP1 
resides in the nucleus, excluding the nucleolus (171), whereas SENP2 localizes 
to the nuclear envelope (172). SENP3 and SENP5 localize to the nucleolus 
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(173,174), whereas SENP6 localizes to the cytosol (175). And SENP7 localizes 
to the nucleoplasm (176).  
Figure6  
A) 
 
 
 
 
 
 
 
Figure 6A). The Sentrin Protease Family. Each SENP family member 
contains a C-terminal catalytic domain. Both SENP6 and SENP7 contain 
additional sequences within their C-terminal domain. The N-terminus of each 
SENP family member contains sequences that impart both sub-cellular 
localization and substrate specificity. 
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B)  
 
 
 
 
 
 
 
 
 
Figure 6B). The SUMO-specific Proteases Dual Functions. Certain 
SUMO-specific proteases (SENPs) are responsible for SUMO precursor 
maturation and cleavage at the C-terminal extension of SUMO. They also cleave 
at the isopeptide bond between the terminal glycine of mature SUMO and the 
lysine of a substrate. The sites of cleavage by SUMO proteases are highlighted 
in pink and the scissile bonds are indicated by the arrow.  
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Previously, the PXR protein has been shown to be modified by SUMO-2/3 
in response to TNF signaling in hepatocytes. The SUMOylated PXR protein 
incorporated SUMO-2/3 chains and the feedback repressed the immune response 
in hepatocytes (132). Therefore, SUMOylation of PXR represents the likely 
molecular basis underlying the inhibition of hepatic immune response in 
Rif-treated patients. Here, we further study the mechanism of the PXR 
SUMOylation and the transrepression mechanism of inflammation. By 
integrating our previous data, the working model has been proposed (Figure 7). 
PXR is SUMOylated by SUMO-1 and/or SUMO-2/3 in response to an 
inflammatory stimulus in a ligand-dependent and/or ligand-independent manner. 
The SUMOylated PXR prevents co-repressor complex dissociation from NF-B 
through protein-protein interactions. In order to test the hypothesis, NF-B target 
gene expression was analyzed in Hepa1-6 cell line, including COX-2, IL-6 and 
IL-1rn. We also used cell-based methods to compare SUMO-1 modification 
capacity with SUMO-3 and an in vitro SUMOylation assay to determine the 
PXR SUMOylation reaction mechanisms. Furthermore, we described the 
substrate preferences of six SENPs and indentified possible SUMOylation site(s) 
based on site-directed mutagenesis. Taken together, the work presented in this 
thesis contributes to understanding the interface between PXR-mediated gene 
activation, the SUMOylation pathway and inflammation. 
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Figure 7 
 
Figure 7. Model of PXR-mediated Transrepression of Inflammatory 
Response Pathway. Co-stimulation of cells with PXR activators and 
inflammatory stimuli leads to the formation of trans-repressive multi-protein 
complexes on the promoters of specific inflammatory-response genes. 
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Materials and Methods 
Cell Culture and Treatment of Hepa1-6 Cells. 
The Hepa1-6 cell line is a readily available immortalized hepatocyte cell line 
isolated from mouse hepatocytes by Darlington et al., in 1980 (177). Studies in 
our laboratory have confirmed that induction of Cyp3a11 and expression of PXR 
is absent in this cell line (data not shown). The Hepa1-6 cell line has been used 
successfully in a variety of studies such as cell hybridization, biochemical 
analysis of tissue-specific gene products, and the modulation of expression of 
genes governing differentiated phenotypes. Hepa1-6 cells were maintained in 
DMEM supplemented with 10% FBS supplemented with pen-strep. 
Sub-culturing was performed at ~70% confluence using a 1:5 dilution. Cells 
were transfected with the indicated plasmids using lipofectamine 2000 per 
manufacturer’s instructions (Invitrogen). Cells were were with treated with 10 
micromolar pregnenalone 16a-carbonitrile (PCN), a well-known mouse PXR 
agonist, for 24 hours. Treatment of cells was continued with lipopolysaccharide 
(LPS, 10 micrograms/ml media) or tumor necrosis factor alpha (TNFa, 10 
nanograms/ml media) in the presence and absence of PCN for an additional 12 
hours.  
 
RNA Isolation and q-PCR Analysis  
Total RNA was isolated from cell culture using a commercially available 
kit (Rneasy, Qiagen) according to the manufacturer’s instructions. RNA was 
visualized by electrophoresis to ensure its integrity. Isolated RNA was DNase 
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treated (Sigma), reverse transcribed (Promega), and quantitative PCR was 
performed using an Applied Biosystems StepOne Plus real-time PCR system to 
detect mRNA expression specific for indicated genes. Fold induction was 
calculated using beta-actin mRNA as a normalization control.  
 
Bacterial Expression and Purification of GST-tagged Fusion Proteins 
GST fusion protein expression vectors were transformed into BL21DE3 cells 
(Novagen #69450-1), which contain the T7 polymerase stably intergrated under 
the control of an IPTG inducible promoter. After plated the plasmid on LB-amp 
(100ug/mL) plates, a single colony was used to inoculate a 10 mL LB liquid 
culture containing 100ug/mL ampicillin.  This culture was grown at 37°C 
shaking for 6 hours. A 15% glycerol stock was prepared from the 10mL culture 
in a final volume of 0.5 mL.  Transformants were inoculated and grown as 
before for 10 hours.  A 50 mL culture was then inoculated and grown as before 
for 2-3 hours.   The culture was induced to express the fusion protein with 0.5 
mM IPTG (0.24g/L) for 4-6 hours.  The cells were pelleted and resuspended in 
5.0mls NETN (NETN=100mM NaCl, 20 mM tris pH=8.0, 1 mM EDTA, 0.5% 
NP-40).  The cells were sonicated 3 times, on a medium setting, for 1 minute 
each on ice.  The sonicated cell lysates were centrifuged at 12,000 rpm for ten 
minutes at 4°C.  The supernatant was made 10% in glycerol and frozen at - 
80°C for future use.  25 µl of glutathione agarose beads (Pharmacia 
#17-0756-01) was added to the 300 µl supernatant of the -80°C frozen 
supernatant after thawing and incubated with shaking at 4°C for 30minutes in  
a 1.5 mL eppendorf tube.  The beads were pelleted for 1 minute and then 
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washed three times in a 1mL NETN. 
In Vitro SUMOylation Assay 
Each SUMOylation reaction (Enzo Life Sciences Inc) contained 1 μM 
recombinant purified PXR in total 20-μl volume in the presence or absence of 
Mg2+-ATP. The assay components including SUMO proteins, E1, E2 and E3 
enzymes were mixed in a microcentrifuge tube and incubated at 30°C for 60 min, 
and the reaction was quenched by the addition of 20 μl of 2× SDS-PAGE gel 
loading buffer. To detect the SUMOylated proteins, a 5-μl sample of each 
reaction was resolved by using 10% SDS-PAGE, and the immunoblot analysis 
was conducted by using anti-PXR antibodies (H-11, Santa Cruz). 
 
 Cell-Based SUMOylation Assay 
Plasmids pcDNA3-6X-His-SUMO1, and pcDNA3-6His-SUMO3 were 
kind gifts from Dr. Ronald T. Hay (University of Dundee, Dundee, United 
Kingdom). For transfection assays, Hepa1-6 cells were grown in six-well dishes 
for 24 h until 80% confluence. Cells were transfected with the expression 
plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Forty-eight 
hours after transfection, cells were washed twice with phosphate-buffered saline 
and harvested in 200 μl of lysis buffer (6 M guanidinium-HCl, 10 mM Tris, 100 
mM sodium phosphate buffer, pH 8.0). After sonication the cell lysates were 
cleared by centrifugation at 3,000 x g for 15 min. The cleared cell lysates were 
mixed with 25 μl of Cobalt-linked agarose (QIAGEN) that had been prewashed 
three times in cell lysis buffer. The mixture was incubated for 2 h on a rotator at 
room temperature and centrifuged for 2 min at 1,000 rpm to gather the beads. 
The beads were washed once in wash buffer I (8 M urea, 10 mM Tris, and 100 
36 
mM sodium phosphate buffer, pH 8.0), three times in wash buffer II (8 M urea, 
10 mM Tris, 100 mM sodium phosphate buffer, pH 6.3, 0.1% Triton X-100, and 
5 mM β-mercaptoethanol, and once in wash buffer III (150 mM NaCl, 10 mM 
imidazole, and 50 mM sodium phosphate buffer, pH 6.75). The beads were 
resuspended in 40 μl of 2× SDS-PAGE gel loading buffer and boiled for 5 min, 
and 20-μl samples were resolved by using 10% SDS-PAGE. The gel was 
transferred to polyvinylidene difluoride membrane using standard methods, and 
immunoblot analysis was performed to detect the SUMOylated form of PXR 
using the H-11 monoclonal anti-PXR antibody. 
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Results 
1. Expression of PXR Transrepresses the Induction of Endogenous 
Inflammatory Response Genes in Hepa1-6 Cells.   
The NF-κB transcription factor is a critical regulator of the host immune 
and inflammatory response in various disease states. We analyzed the NF-κB 
target gene mRNA levels by RT-qPCR in Hepa1-6 cell line, which is a 
derivative of the BW7756 mouse hepatoma arose in a C57/L mouse. As there is 
no endogenous PXR protein expressed in Hepa1-6 cell line, we transfected the 
cells with mouse PXR or mock plasmid as indicated and treated with mouse 
PXR activator PCN for 24 hours. Cells were then treated for an additional 12 
hours with LPS in the presence and absence of PCN as indicated. We isolated 
total RNA and examined the relative expression levels of several known NF-κB 
target genes (Figure 8).  
Previous study of the expression levels of genes encoding TNFα, IL-6, 
IL-1α, and IL-1β showed that these genes are significantly induced when PXR is 
ablated in PXR-KO mice (132). To confirm the involvement of PXR in 
anti-inflammation process, we first tested inflammatory response genes in 
Hepa1-6 cells in the absence of PXR. 
Among the four non-transefected groups (Veh, PCN, LPS, PCN+LPS), 
analysis of the expression levels of genes encoding Cox-2, IL-6 and IL-1rn using 
RT-qPCR showed that their levels were significantly increased in LPS-treated 
group. These results reveal an active role for 12h LPS treatment in inducing the 
expression of genes that encode key inflammatory cytokines. Also, in the 
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absence of mouse PXR, there was no difference between LPS and PCN+LPS 
co-treatment groups, which proved that Hepa1-6 cell line is an ideal cell model 
to study PXR-dependent effect. 
In order to investigate the repressive role of PXR on NF-κB-mediated 
inflammatory signaling pathway, we analyzed the gene expression levels in 
mouse PXR-transfected groups. When mouse PXR was activated by PCN, the 
endogenous inflammatory cytokines were repressed about one fold. When cells 
were challenged with LPS stimulation, mouse PXR-transfected cells were highly 
resistant to LPS-induced cytokine up-regulation (~10 fold). These data provide 
supporting evidence for establishing the existence of transcription factor 
crosstalk between the PXR and NF-κB in liver cells. 
We next determined ligand-dependent or ligand-independent effect of 
mouse PXR on its activity. When mouse PXR was activated by PCN, the 
ligand-activated mouse PXR repressed LPS-induced gene expression at the 
comparable level to that of non-liganded mouse PXR. The results suggested that 
mouse PXR repressed NF-B signaling pathway in a ligand-independent manner 
in Hepa1-6 cells.  
The underlying molecular mechanism(s) responsible for the PXR repressive 
effect on inflammatory genes has been proposed. In response to LPS activation, 
PXR is SUMOylated by endogenous SUMO proteins at low stoichiometry. The 
SUMOylated PXR is highly dominant efficient to repress NF-B transcriptional 
activity through protein-protein interactions, instead of direct DNA binding. 
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Figure 8 
 
 
Figure 8.  Expression of PXR Transrepresses the Induction of Endogenous 
Inflammatory Response Genes in Hepa1-6 Cells.  Cells were transfected 
with mouse PXR or mock-transfected as indicated and treated with 10 mM PCN 
for 24 hours. Cells were treated for an additional 12 hours with LPS in the 
presence and absence of PCN as indicated.  Gene expression levels of indicated 
endogenous inflammatory response genes were determined using real-time PCR 
as described in Materials and Methods. Data were expressed as the fold 
induction over the vehicle and were reported as the mean +/- SEM of three 
independent reactions.  
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2. The PXR Protein Is SUMOylated in vitro 
To demonstrate that PXR is a substrate of SUMOylation, we first analyzed 
the PXR SUMOylation mechanism in vitro. There are 28 lysine residues on 
human PXR protein (Figure 9-1). Previously, the bioinformatic approach has 
been used to scan the amino acid sequence of human PXR for the presence of a 
consensus SUMOylation site (132). Using this strategy we identified four 
potential sites. Since the four sites are all located in the C-terminal hinge domain 
and LBD, the PXR protein was cut into two parts for the in vitro SUMOylation 
assay. The first part included AF-1 and DBD domains and was named as human 
PXR-DBD (1-105 amino acids). The second part included hinge domain, LBD 
and AF-2 domains and was referred as human PXR-LBD (106-434 amino 
acids).  
    The strategy shown in Figure 9-2 was followed to express, isolate and 
purify GST-tagged human PXR DBD and GST-tagged human PXR LBD 
proteins.  Purified components were collected, separated on SDS-PAGE gels, 
and visualized by staining with Coomassie blue (Figure 9-3). As shown, the 
bands at 26kD in GST-human PXR DBD and LBD proteins lanes are 
de-associated GST proteins. The GST-human PXR LBD (64 kD) migrated 
slower than the GST-human PXR DBD (37kD) protein on the gel and we 
noticed that the higher molecular-weight protein was more degraded and less 
soluble in buffers.  
We next used in vitro methods to determine the extent to which purified 
recombinant GST-human PXR LBD served as a substrate in the 
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SUMO-conjugation pathway. We incubated GST-tagged purified recombinant 
human PXR LBD in vitro together with E1, E2, E3, and SUMO-1 or SUMO-3 
proteins in the presence or absence of the required magnesium and ATP 
co-factors. The extent of SUMOylation after the incubation was determined by 
SDS-PAGE and Western blot analysis with anti-hPXR monoclonal antibodies 
(Figure 9-4). This type of analysis revealed that the human PXR LBD protein 
can serve as an effective substrate for both SUMO-1 and SUMO-3 in the 
SUMO-conjugation pathway in vitro. And the in vitro SUMOylation of 
GST-human PXR LBD was strongly enhanced by E3 ligase PIASy. There is one 
primary SUMOylation band (~110kD) when either SUMO-1 or -3 was used in 
the reaction, which indicated human PXR LBD could be SUMOylated at one 
primary site in vitro. When we compared the molecular mass shift of the 
SUMO-1 modified band with SUMO-3 modified band on the blot, SUMO-1 
conjugated PXR appeared at a higher molecular weight. And this is in consistent 
with the fact that SUMO-1 protein is larger in size than SUMO-3 protein. It is 
noteworthy that addition of PIASy dramatically enhanced SUMO modifications 
in vitro. In order to figure out whether GST-human PXR LBD could be 
SUMOylated without E3 in vitro, a blot with longer exposure time was shown in 
Figure 9-4 lower panel. The results suggested that GST-human PXR LBD was 
able to be SUMOylated to less extent by both SUMO-1 and SUMO-3 in the 
absence of E3 in vitro. The data presented indicated that SUMO-1 and SUMO-3 
could modify GST-human PXR LBD in vitro, and SUMOylation was enhanced 
by PIASy. Although the in vitro assay is highly suggestive of potential PXR 
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SUMO modification, it is still necessary to examine PXR SUMO conjugation in 
cultured cell lines or primary cells.  
Figure 9-1 
 
 
Figure 9-1.  Structure and Post-translational Modification of Human PXR 
Lysine Residues. A) All the lysine residues on human PXR were determined 
and there are 28 lysine residues. The human PXR protein was analyzed for the 
presence of the consensus SUMOylation sequences as defined by an online 
SUMO Plot server (http://www.abgent.com/tools/SUMOplot).  This type of 
bioinformatic analysis identifies four potential sites for SUMOylation, one of 
which is predicted as a “high probability” SUMOylation site and three others 
that are predicted as “low probability” SUMOylation sites. 
Figure 9-2 
 
 
 
 
 
Figure 9-2. Purification Scheme for GST-tagged Proteins.  
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Figure 9-3 
A)                                  B) 
 
 
Figure 9-3. SDS-PAGE Analysis of Purified Proteins. A) GST and 
GST-human PXR DBD proteins were separated on a 12.5% gel. B) GST-human 
PXR LBD protein was separated on a 10% gel.  Proteins were visualized by 
staining with Coomassie blue. The purified proteins are indicated with asterisks.  
 
 
 
 
GST  GST-human PXR 
DBD 
GST-human PXR 
LBD 
* 
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Figure 9-4  
 
 
Figure 9-4. In Vitro SUMOylation of GST-human PXR LBD by SUMO-1 
and SUMO-3 is enhanced by PIASy.  The recombinant purified GST-human 
PXR LBD fusion protein was incubated together with E1, E2 in the presence and 
absence of Mg
2+
-ATP as indicated.  The recombinant purified E3 ligase (PIASy) 
was included as indicated.  Input protein Coomassie stained gel is shown in the 
inset at the right (Input).  Five microliter aliquots of the in vitro SUMOylation 
reaction were resolved using 10% SDS-PAGE and western blotting was 
performed using anti-human PXR monoclonal antibodies to detect 
SUMO-modification. The long-exposure blot is shown at the lower panel.  
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3. PXR is Preferentially SUMOylated in Hepa1-6 Cells by SUMO-3 and 
PIASy. 
We initiated a series of studies using an over-expression and transfection 
approach in Hepa1-6 and HeLa cells (132). Co-transfection of Hepa1-6 cells 
with 1) the human PXR expression vector, 2) the 6×His-SUMO-1 or 
6×His-SUMO-3 expression vector and 3) the PIAS1 or PIASy E3 enzyme 
expression vector allows the rapid and selective purification of SUMOylated 
forms of PXR using cobalt-linked agarose beads and a strong denaturing buffer 
containing high levels of guanidine-HCl. The reason for choosing cobalt beads 
instead of nickel beads is that cobalt beads exert stronger and more specific 
binding to SUMOylated human PXR (data not shown). But the human PXR 
might still non-specifically bind to cobalt beads through zinc fingers. 
 Hepa1-6 cells have endogenous E1 and E2 enzymes which can support 
PXR SUMO modification efficiently without over-expression of E1 and E2. The 
endogenous SENPs that would probably cleave SUMOylated forms of PXR 
during cell lysis are rapidly de-activated under denaturing conditions.   
Based on this experimental approach we detected SUMOylated PXR using 
a Western blot analysis with the α-human PXR monoclonal antibody (Figure 
10-1). When human PXR alone was exogenously expressed, the un-conjugated 
human PXR (~52kD) was pulled down by cobalt-linked beads which represented 
the non-specific binding. When His-tagged SUMO plasmid and E3 ligase PIAS 
were co-transfected, the un-conjugated human PXR was detected along with a 
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series of higher molecular weight proteins that represented SUMO-conjugated 
human PXR.  
The over-expressed SUMO-3 protein formed chains on the human PXR 
protein, which were present at a much higher level in cells transfected with 
PIASy compared with those transfected with PIAS1(Figure 10-1 lane 4 and 5). 
We also used SUMO-2/3 antibody to detect global SUMO-2/3 modification 
(Figure 10-2). PIASy preferentially increased global SUMO modification by 
SUMO-2/3 to a higher level compared with PIAS1. The whole cell lysates of 
Hepa1-6 cells were subjected to detection of endogenous SUMO-2/3 proteins. 
Consistent with the prevailing theory that SUMO-2/3 remains in a free or 
un-conjugated form under normal condition (178), the Hepa1-6 whole cell 
lysates showed endogenous free and un-conjugated SUMO-2/3 proteins (Figure 
10-3 lower panel).  
PXR could also be SUMOylated by SUMO-1 in our cell-based assay, 
although we found that human PXR was preferentially modified by SUMO-3. 
SUMO-1 cannot form chains on PXR since its self did not possess consensus 
SUMO sequences. PIASy preferentially promoted SUMO-1 modification both 
on human PXR and global proteins as shown in Figure 10-4. When the blot was 
over-exposed, the free His-tagged SUMO-1 was shown to be present (Figure 
10-4 middle panel). Besides endogenous SUMO-2/3, the Hepa1-6 cells 
contained endogenous SUMO-1 protein as well (Figure 10-1-C lower panel).  
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Figure 10-1  
A)  
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B)  
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C)  
 
 
 
 
 
 
 
 
 
 
Figure 10-1. Detection of SUMOylated Human PXR Protein in Hepa1-6 
Cells.   The human PXR protein was co-expressed in Hepa1-6 cells with 
6X-His-tagged SUMO-1 or SUMO-3, and E3 enzyme (PIAS1 or PIASy). After 
48h transfection, cells were lysed using denaturing buffer containing 
guanidinium hydrochloride to inactivate de-SUMOylation enzymes. 
SUMOylated proteins were purified by cobalt-linked agarose beads. Purified 
His-tagged proteins and Hepa1-6 whole cell lysates were resolved using 
SDS-PAGE and subjected to Western blot analysis using antibodies that 
recognize A) human PXR or B) SUMO-2/3 or C) SUMO-1 as indicated.  
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4. The hPXR-K108 Residue Is A SUMOylation Site. 
It was previously reported that human PXR contains multiple SUMO 
consensus sequences and that one site, K108, is of high probability (Figure 9-1). 
To directly assess K108-SUMO conjugation capacity, the PXR protein 
containing site108 lysine-to-arginine mutation was employed. We used 
cell-based assay to detect the extent of human PXR-K108R SUMO-1 and 
SUMO-3 modification (Figure 11). The K108R mutation down-regulated, but 
did not blocked the SUMOylation of PXR. The result indicated that K108 was 
involved in both SUMO-1 and SUMO-3 conjugation pathway. The monomeric 
SUMO modified-PXR still existed which suggested there were other potential 
SUMOylation sites besides K108, which calls for further analysis. Another thing 
to note is that endogenous SUMO-2/3 proteins may contribute to unexpected 
migrating form of human PXR detected in SUMO-1 over-expression groups 
because the endogenous free-state SUMO-2/3 in Hepa1-6 cells is likely to be 
conjugated to human PXR when PIASy is over-expressed. 
5. Inflammatory Mediator LPS Induces SUMOylation of Human PXR 
Wide Type and K108R Mutant. 
We next sought to determine if inflammation could influence SUMOylation 
of PXR in Hepa1-6 cells. Previous results performed in human hepatocytes 
reported that treatment of cells with TNFα alone or TNFα together with Rif 
produced an increased level of SUMO-2/3 modified PXR (132). The 
identification of PXR SUMO(1)ylation raised the question of whether LPS also 
induced SUMO-1 conjugation to PXR.  
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 The Hepa1-6 cells were transfected with plasmids that express human 
PXR, His-tagged SUMO-1 and E3 PIASy. Transfected cultures were subjected 
to vehicle treatment (Figure 12-1, lane1) or LPS treatment for 12 hours (Figure 
12-1, lane 3). SUMO-modified proteins were purified after drug treatment using 
cobalt bound beads and PXR protein was examined on Western blots. As 
expected, LPS-treated cells significantly induced SUMO(1)ylation of human 
PXR at 12 hrs (Figure 12-1, lane 3).  
Some NR ligands enhance SUMOylation of target NR family members 
(e.g., LXRα and PPARγ), but this has not been detected for PXR. Transfected 
Hepa1-6 cells were treated with either vehicle (DMSO) (Figure 12-1, lane 1) or 
the human PXR ligand Rif (Figure 12-1, lane 2) for 36 hours before harvest. Rif 
treatment significantly decreased SUMO(1)ylation of human PXR compared 
with vehicle (Figure 12-1, lane 1). Next we compared ligand treatment group 
with co-treatment group comprising of both ligand pre-activation and 
inflammatory stimulation (Figure 12-1, lane 4). LPS co-treatment ameliorated 
ligand-induced down-regulation of PXR SUMO1 modification. These results 
indicated that inflammatory signaling induced both non-liganded and 
ligand-bound PXR SUMO-1 modification.  
    Since K108 is one of the potential SUMO acceptor sites, we next analyzed 
human PXR K108R SUMO-1 conjugation levels in response to LPS stimulation. 
As shown in Figure 12-2 left panel, LPS induced SUMO-1 modification on 
human PXR K108R mutant at a comparable level to that of wide type human 
PXR. The global SUMO-1 conjugations in response to LPS did not distinguish 
between over-expressed wide type and mutated human PXR groups. The data 
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revealed a tentative result that K108 was not required for LPS-inducible PXR 
SUMOylation.  
Figure 11 
 
 
 
 
 
 
 
 
 
 
Figure 11. The Lysine Residue 108 Mutation Decreases PXR SUMOylation. 
Hepa1-6 cells were transfected with His-tagged SUMO1 or SUMO3 and either 
human PXR or human PXR-K108R. The ~75kDa bands were SUMOylated PXR 
and were reduced in human PXR-K108R SUMO-1 and SUMO-3 conjugation 
groups.  
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Figure 12-1 
 
Figure 12-1. Inflammatory Stimulus and Ligand Modulate Wide Type 
Human PXR Protein SUMO-1 Modification in Hepa1-6 Cells.  Hepa1-6 
cells were transfected with human PXR, PIASy and His-tagged SUMO1, or 
SUMO-3. Cells were treated for 36 hours with vehicle or Rif (10 μM) or LPS (10 
mg/ml) for 12 hours, or Rif (10 μM) pre-treatment together with LPS (10 mg/ml) 
12 hours co-treatment. The cells were harvested 48hrs post-transfection and 
purified proteins were immunoblotted with anti-human PXR. 
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Figure 12-2 
 
 
 
 
 
 
 
 
Figure 12-2. K108 Is Not the Primary LPS-inducible SUMOylation residue. 
Hepa1-6 cells were transfected with SUMO-1 and either human PXR or human 
PXR-K108R and treated with vehicle or LPS (10 mg/ml) for 12hrs before 
harvest. The purified protein extracts were analyzed by immunoblotting with 
PXR monoclonal antibody and anti-SUMO1 antibody. 
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6. Sentrin Proteases Differentially De-SUMOylate PXR-SUMO 
Conjugates in Hepa1-6 Cells. 
Because SUMOylation is a reversible pathway, we next studied the 
reversibility of PXR SUMOylation reaction and how SUMOylated PXR may be 
selectively processed by six distinct mammalian SUMO proteases.  
We first examined the capability of SENP1, -2, -3, -5, -6 and -7 to 
de-conjugate SUMO-1 from PXR. All SENPs were expressed as N-terminal 
Flag fusions, and Hepa1-6 cells were transfected with expression plasmids 
encoding His-tagged SUMO-1 and PIASy. Because His-tagged SUMO-1 was 
expressed as the C-terminally processed Gly-Gly form, our de-conjugation 
assays in Hepa1-6 cells compared merely the isopeptidase activity of different 
SENPs. As shown in Fig. 13-1, SENP1 and SENP2 were potent in removing 
SUMO-1 from human PXR protein. The isopeptidase function of SENP3 was 
very weak on SUMO-1-modified human PXR. SENP5, 6 and 7 showed no 
activity on SUMO-1 conjugates (Figure 13-1). 
We next compared the isopeptidase activity of the SENPs toward human 
PXR-SUMO-3 conjugations in Hepa1-6 cells. In line with the above results for 
human PXR-SUMO-1 conjugates de-SUMOylation, both SENP1 and SENP2 
were efficient in de-conjugating SUMO-3 from human PXR in Hepa1-6 cells. 
Interestingly, SENP3 and 5 were also capable of de-conjugating SUMO-3 to 
some extent. Thus, SENP3 and SENP5 appeared to show preference for 
SUMO-3 conjugates. SENP6, which showed no activity on human 
PXR-SUMO1 modifications in Hepa1-6 cells, was efficient toward human 
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PXR-SUMO3 conjugates. It completely removed SUMO3 chain formation. 
SENP7 was characterized as a SUMO-2/3-specific protease that was likely to 
regulate poly-SUMO-2/3chains rather than SUMO-1 conjugation (176). 
However, SENP7 had no effect on removing SUMO-3 from the hPXR–SUMO3 
conjugates (Figure 13-2). 
 Mutation of the catalytic cysteine in the C-terminal of SENPs to serine has 
been shown to inactivate their catalytic function (179). We used the mutants 
SENP1C603S, SENP2C466S, SENP3C532S, SENP5C713S, and 
SENP6C1030S as controls in Hepa1-6 cells de-SUMOylation assays. In keeping 
with the importance of the conserved cysteine residue for the fully catalytic 
function of SENPs, the mutated SENPs were totally inactive in de-conjugating 
SUMOs from cellular proteins (Fig. 13-1 and 13-2).  
Taken together, these results identified SENP1 and SENP2 as strong 
candidates for SUMO-specific proteases reversing PXR SUMOylation by both 
SUMO-1 and SUMO-3 in cells. SENP3 and 5 showed substrate preferences 
towards SUMO-3 conjugates. SENP6 effectively removed SUMO-3 poly-chain 
formation. SENP7 had no effect on PXR SUMOylation.  
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Figure 13-1  
 
 
 
 
 
 
 
 
 
Figure 13-1. Cell-based Analysis of Human PXR 
SUMOylation/De-SUMOylation by SUMO1 and Sentrin Proteases in 
Hepa1-6 Cells. Indicated mammalian expression vectors are transfected using 
lipofectamine per manufacturer’s instructions.  Forty-eight hrs post-transfection 
cells were lysed as described in Materials and Methods.  Proteins were resolved 
using 10% SDS-PAGE and western blotting was performed using anti-human 
PXR monoclonal antibody. m1:SENP1C603S, m2: SENP2C466S, m3: 
SENP3C532S, m5: SENP5C713S, m6: SENP6C1030S 
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Figure 13-2 
 
 
 
 
 
 
 
 
 
Figure 13-2. Cell-based Analysis of Human PXR 
SUMOylation/De-SUMOylation by SUMO-3 and Sentrin Proteases in 
Hepa1-6 Cells. Indicated mammalian expression vectors are transfected as 
described.  Proteins were resolved using 10% SDS-PAGE and western blotting 
was performed using anti-human PXR monoclonal antibody.  
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7. SENP6 together with Human PXR Mutants Provide Insights into 
PXR SUMOylation Sites Prediction 
Taken together, the results shown above suggest that 1) The ~75kD band is 
the primary human PXR SUMOylation band, 2) K108 is one of the potential 
SUMOylation sites, 3) The ~110 kD band indicates that there are two SUMO 
proteins conjugated to PXR. We hypothesized that there were two major 
SUMOylation sites. As discussed above, Hepa1-6 cells have high amount of 
endogenous SUMO-2/3 proteins which may lead to chain formation.  
In order to further map PXR SUMOylation sites, human PXR-K108R was 
transfected together with SENP6 to remove all possible SUMO chain formation. 
As shown in Figure 14-1, human PXR-K108R mutation together with SENP6 
isopeptidase left two monomeric bands (~75 kD and ~110kD). The data suggest 
that there could be at least three SUMO-3 modifiable sites on human PXR 
(Figure 14-1). 
    When we looked at SUMO-1 modification, we found that SENP6 cleaved 
the higher molecular bands on hPXR-K108R and left one primary monomeric 
SUMO-1 site (~75kD). We speculated that two major sites were modified by 
SUMO-1 (Figure 14-2).  
The double mutants and triple mutants were used to further analyze the 
potential SUMOylation sites. The systematic site-directed mutagenesis approach 
revealed two major sites of SUMOylation at positions K108 and K128 on the 
human PXR protein. The K108R, K128R double mutant could not be modified 
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by SUMO-1 (Fig 14-3 lane 7); whereas it could still form monomeric conjugates 
by SUMO-3 (Fig 14-4 lane7) (~75kD).  
Figure 14-1  
  
 
 
 
 
 
 
 
 
Figure 14-1. Detection Wide Type Human PXR and Human PXR-K108R 
Mutant SUMO-3 Modification in Hepa1-6 Cells. The human PXR protein or 
hPXR-K108R was co-expressed in Hepa1-6 cells together with His-tagged 
SUMO3 proteins, E3 enzyme PIASy and SENP6. After 48h transfection, cells 
were lysed and SUMOylated proteins were purified by using cobalt-linked 
agarose beads. Purified proteins were resolved using SDS-PAGE and subjected 
to Western blot analysis using antibodies that recognize human PXR as 
indicated.  
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Figure 14-2 
 
Figure 14-2. Detection Wide Type Human PXR and Human PXR-K108R 
Mutant SUMO-1 Modification in Hepa1-6 Cells. The human PXR protein or 
hPXR-K108R was co-expressed in Hepa1-6 cells together with His-tagged 
SUMO1 proteins, E3 enzyme PIASy and SENP6. After 48h transfection, cells 
were lysed and SUMOylated proteins were purified by using cobalt-linked 
agarose beads. Purified proteins were resolved using SDS-PAGE and subjected 
to Western blot analysis using antibodies that recognize human PXR as 
indicated.  
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Figure 14-3 
 
 
 
 
 
 
 
 
Figure 14-3. PXR is Mainly SUMOylated in the Hinge Domain by SUMO-1. 
The human PXR protein and seven human PXR mutants were expressed in 
Hepa1-6 cells together with His-tagged SUMO1 proteins and E3 enzyme PIASy. 
After 48h transfection, cells were lysed and SUMOylated proteins were purified 
by using cobalt-linked agarose beads. Purified proteins were resolved using 
SDS-PAGE and subjected to Western blot analysis using antibodies that 
recognize human PXR as indicated.  
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Figure 14-4 
 
 
 
 
 
 
 
Figure 14-4. PXR is Mainly SUMOylated in the Hinge Domain by SUMO-3. 
The human PXR protein and seven human PXR mutants were expressed in 
Hepa1-6 cells together with His-tagged SUMO3 proteins and E3 enzyme PIASy. 
After 48h transfection, cells were lysed and SUMOylated proteins were purified 
by using cobalt-linked agarose beads. Purified proteins were resolved using 
SDS-PAGE and subjected to Western blot analysis using antibodies that 
recognize human PXR as indicated.  
 
 
 
 
 
64 
Discussion 
1. PXR SUMOylation/De-SUMOylation Mechanism 
1.1 SUMO-1 versus SUMO-2/3 
The PXR protein belongs to a family of ligand-activated transcription 
factors that regulate xenobiotic response and drug metabolism in liver and 
intestine. Recent studies have characterized PXR as a regulator of hepatic innate 
and adaptive immune response. PXR agonist Rif exerts immunological effect 
(122) and PXR is required for normal immunity to bacterial infection (180). In 
addition, PXR activation inhibits LPS induction of a number of 
pro-inflammatory genes (132). Repression of inflammatory mediator by PXR 
agonists is abolished in hepatocytes lacking PXR indicating that PXR mediates 
this anti-inflammatory response (181).  
Although recent results have provided a link between xenobiotic 
metabolism and inflammation, relatively few mechanisms have been established 
for the transrepression pathway regarding the post-translational modification of 
the human PXR protein. Our lab has previously identified that PXR 
SUMOylation is implicated to repress inflammatory response in hepatocytes 
(132).  
Here we provided direct evidence of PXR modification by both SUMO-1 
and SUMO-2/3. Previous study showed the existence of endogenous 
un-conjugated form of SUMO-2/3 in great abundance and the free state 
SUMO-1 to a lesser extent in COS-7 cells (178). In our mouse hepatoma cell 
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model, both SUMO-1 and SUMO-2/3 are endogenously expressed in the 
un-conjugated form with the potential capacity to modify cellular proteins. 
Over-expression of SUMO proteins and E3 ligases markedly increased the level 
of human PXR modification by both SUMO-1 and SUMO-3. Furthermore, 
compared with SUMO-1, PXR was preferentially targeted by SUMO-3 which 
formed poly-SUMO chains in vivo.  
In vitro SUMOylation assays showed that PXR LBD was a substrate for 
both SUMO-1 and SUMO-3. PXR LBD was preferentially targeted by SUMO-1 
rather than SUMO-3 in vitro which contradictory to the cell-based result. 
However, it is questionable whether the in vitro SUMOylation assays could 
faithfully reproduce physiological substrate selection mechanisms. 
The endogenous free and un-conjugated SUMO-2/3 is readily available for 
conjugation reactions when a series of stress-responsive kinase cascades is 
activated in response to cellular stresses such as heat shock (178), 
hypoxia/ischemia (182) and oxidative stress (183), whereas SUMO-1 
modification level appears to be unaffected (184).  The increase of 
incorporation of SUMO-2/3 into PXR and formation of SUMO-2/3 chains were 
found in response to TNF stimulation and the feedback mediated active 
repression of NF-B activity in hepatocytes (132). Here, we found that SUMO-1 
modification of PXR was also induced in LPS-mediated inflammatory response 
in Hepa1-6 cells. On the contrary, ligand activation was observed to lead to a 
reduction in the amount of SUMO-1 conjugation to PXR. Such changes in 
modification have been observed by other NRs as well, for example PPAR2 
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(185) and VDR (186). Ligand binding might induce PXR conformation changes 
which results in reduced accessibility of acceptor sites to SUMO modification.  
Since we only utilized Hepa1-6 cell line in our studies, future work on 
detecting SUMO-1 modification of endogenous human PXR in primary cultures 
in response to inflammatory stimulation is necessary. If inflammation actively 
induced endogenous PXR SUMO-1 conjugation in human hepatocytes, we could 
further focus on a comparison of functional consequences between SUMO-1 
conjugation and SUMO-3 conjugation. It is possible that SUMO-1- and 
SUMO-3-dependent transrepression pathways converge on the regulation of 
NCoR clearance from inflammatory response genes. It will be of interest to 
study the signal-specific and gene-specific usage of the two parallel pathways by 
PXR. Also characterization of proteins specifically modified by SUMO-2/3 or 
SUMO-1 in a stress-responsive manner and the fate of such SUMO-modified 
proteins is an interesting question to study.  
It has been shown that SUMO-2/3 possesses the capacity to form polymeric 
chains via lysine 11. Interestingly, SUMO-1 has been found to be conjugated to 
lysine 11 on SUMO-2/3, suggesting that SUMO-1 may act as a SUMO-2/3 
chain terminator in vivo (187). The physiological significance of these polymeric 
forms of SUMO-2/3 requires further discussion. Intriguingly, it has been 
reported that ubiquitination was induced in response to a variety of cellular 
damages and environmental stresses such as heat shock, oxidative stress, viral 
infection, or mutation (188,189), which results in rapid degradation of damaged 
cellular proteins by 26S proteasomes. Because many proteins are substrates for 
both SUMO and ubiquitin, it has been suggested that SUMO might compete 
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with ubiquitin for the same lysine residue and stabilize the target protein by 
preventing ubiquitin-mediated proteasomal degradation. For example, SUMO-1 
modified IB lysine 21 conferred the resistance to TNF-induced 
ubiquitination and degradation of IB (190). However, it is now clear that 
SUMO-2/3 chains can act as signals for the recruitment of E3 ubiquitin ligase 
RING finger protein 4 (RNF4) that ubiquitylates SUMO chains and degrades the 
proteins modified with SUMO chains (191). For example, promyelocytic 
leukemia (PML) has been identified as the first substrate in the SUMO chain 
formation dependent ubiquitination and degradation pathway in response to 
arsenic (191-193). Further studies are needed to study PXR ubiquitination and 
SUMOylation crosstalk and determine the mutual effects between SUMO-2/3 
chain and poly-ubiquitin chain formation. 
Moreover, the relative reaction kinetics of SUMO-1 and SUMO-2/3 
conjugation to PXR has not been studied. Based on current findings, we 
hypothesize that SUMO-2/3 conjugation is rapidly induced, whereas SUMO-1 
modification acts later on. The rapid kinetics of SUMO-2/3 reaction may reveal 
highly dynamic regulation of the SUMO-2/3 modification in the context of 
inflammatory stress. 
1.2 E3 Ligases 
Initially not clear whether E3 ligases are required in the SUMOylation 
process because SUMO conjugation could take place in two enzymatic steps in 
vitro, including E1 and E2 (194). However, the majority of SUMOylation 
reactions in yeast are E3-dependent (162,195). Later, E3 ligases have been 
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shown to enhance SUMO attachment to many substrates both in vitro 
(163,196,197) and in vivo (164,198,199). Our in vitro SUMOylation assays 
revealed that PXR could be SUMOylated in two enzymatic steps in vitro, 
whereas PIASy enhanced the reaction capacity greatly.  
We also suggest that both PIAS1 and PIASy could function as E3 ligases in 
cell-based assays. PIASy showed stronger E3 ligase functional activity on 
targeting both PXR and overall cellular substrates than that of PIAS1 in vivo. 
However, some previous studies indicated that although cells were 
over-expressed with the same amount of PIAS protein expression plasmids, the 
protein expression levels of each PIAS protein were different (200). Future work 
on analysis of PIAS1 and PIASy protein levels after transient transfection is 
required before we make the absolute conclusion that PIASy is a stronger E3 
ligase to enhance PXR SUMOylation than PIAS1 in vivo. 
The PIAS proteins have also shown preferences in selection of SUMO 
isoforms to be attached to PXR. We showed that PIAS1 and PIASy 
preferentially enhanced PXR modification by SUMO-3 rather than by SUMO-1. 
Another group has found that the transcription factor GATA-2 was SUMOylated 
and that PIASy could increase the extent of this modification, especially in the 
case of the SUMO-2 isoform (201). Therefore, it is tempting to speculate that 
PIAS proteins favor SUMO-2/3 over SUMO-1 in the SUMOylation reactions of 
transcription factors. 
Besides the E3 ligating enzymatic activity, PIAS proteins have also been 
identified to regulate gene transcription through other mechanisms. PIASy has 
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been found to repress the transcriptional activity of AR independent of 
SUMOylation. It exerted repressive effects through the distinct repression 
domains and the recruitment of HDACs to the promoter region of AR target 
genes (202). In another case, PIAS1, but not other PIAS proteins, blocked the 
DNA binding activity of activated Stat1 and inhibited Stat1-mediated gene 
activation in response to interferon signaling (203). PIAS proteins-mediated 
subnuclear sequestration of transcription factors might represent another 
mechanism. For example, PIASy could target lymphoid enhancer factor 1 (LEF1) 
to nuclear bodies through the RING domain, which leads to the repression of 
LEF1 activity (163). It is unknown as to whether or not PIAS proteins could 
repress PXR trans-activation independent of SUMOylation through reducing 
PXR DNA binding activity, enhancing co-repressor recruitment, inhibiting the 
interaction with co-activator or subnuclear sequestration of PXR to nuclear 
bodies. 
1.3 De-SUMOylation 
In keeping with previous findings, our results support that the SENPs are 
functionally different in their ability to de-conjugate SUMOylated PXR. In 
particular, we found out that SENP3 and SENP5 prefer SUMO-3 monomeric 
conjugates. This is unlike SENP1 and SENP2, which can de-conjugate both 
SUMO-1 and SUMO-3. SENP2 removed SUMO conjugates completely; 
otherwise SENP6 efficiently removed SUMO-3 poly-chains.  
The SENPs were shown to localize differently in cells. We need to further 
analyze the localization of SENPs in Hepa1-6 cells when cells are co-transfected 
70 
with PXR and SUMO plasmids. We postulate that in the absence of PXR, 
SENP1 shows primarily a nuclear localization. But SENP5 may reside mainly in 
nucleoli. By analyzing the co-localization of SUMOylated PXR and SENPs, we 
are able to distinguish the mechanism of their substrates specificity. If SENP1 
was co-localized with SUMO-1-conjugated PXR and SENP5 was completely 
sequestered from SUMO-1-modified PXR, we might relate the different 
sub-cellular localization to the alternative isopepetidase activities of the SENPs.  
Since SENPs are functionally different towards targets, the overall 
conjugation state of SUMO-1- and SUMO-2/3 modified proteins may in part be 
regulated at the level of de-conjugation rather than conjugation (204). The 
activity of SENPs was regulated by cellular conditions through control of their 
stability. For example, SENP3 was rapidly degraded under basal condition. In an 
oxidative state, the ubiquitin–proteasome pathway mediated degradation of 
SENP3 was inhibited. SENP3 re-distributed from the nucleolus to the 
nucleoplasm where it participated in the removal of SUMO-2/3 from a number 
of proteins under mild oxidative stress. Since SENP3 did not de-conjugate 
SUMO-1, the SUMO-1 conjugated protein level was not affected by oxidative 
stress stimulation (205). From this point of view, the different activity or 
stability of substrate-specific SENPs may account for the disparate SUMO 
conjugation patterns. 
Previously, we found that the co-expression of SUMO-3 and Ubc9 in CV-1 
cells had no effect on a PXR-response element luciferase reporter gene 
(XREM-LUC) (132). While SUMOylation of PXR did not inhibit its 
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trans-activation, little is known regarding the effect of de-SUMOylation of PXR 
by SENPs on transcriptional activation. 
Several results revealed that de-SUMOylation by SENPs increased NRs 
transcriptional activity through different mechanisms. The studies discussed 
above (205) showed that the increased SENP3 activity under oxidative state 
de-SUMOylated p300, which is a co-activator of HIF1. HIF1is a 
master-regulator of stress-responsive genes (206) and SUMOylation of the p300 
protein inhibited HIF1transcription activity (207). Therefore, by 
down-regulating co-activator p300 SUMOylation level, SENP3 promoted 
HIF1trans-activation of stress-responsive genes under oxidative stress (205). 
Another study on SENP1 and AR showed that SENP1 could increase AR 
transcriptional activation. It was not mediated by de-conjugation of SUMO from 
AR but through de-SUMOylation of HDAC1, a component of co-repressor 
complexes (208). HDAC1 is modified by SUMO-1 in vivo, which is essential for 
its repressive function (209). SENP1 inhibited the transcriptional repressive 
effect of HDAC1 through de-conjugating HDAC1 SUMO-1 modification, which 
in turn enhanced AR transcription activity (208). The effect of SENPs on 
PXR-mediated transcription activity has not been uncovered. Whether SENPs 
modulate PXR activity through de-conjugating SUMOylation of PXR itself or of 
its co-regulators is currently unknown. Therefore, it is of interest to study the 
potent regulatory activity of SENPs that modulate transcription systems in order 
to further understand the biological functions of SUMOylation/de-SUMOylation 
in a big picture. 
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1.4 PXR SUMOylation Sites 
The bioinformatic approach to scan the sequence of PXR for the presence 
of a consensus SUMO acceptor site identified four potential sites within human 
PXR. Since the four sites are all located in the C-terminal hinge domain and 
LBD domain, we tested the SUMOylation capability of the recombinant protein 
composed of human PXR hinge and LBD parts in vitro. The hinge and LBD 
domains were SUMOylated by both SUMO-1 and SUMO-3 in vitro which is 
consistent with our hypothesis that SUMOylation sites reside in the C-terminal. 
However, it is likely that SUMO may be attached to non-consensus lysine 
residue, thus the total 28 lysine residues on PXR were analyzed systematically 
based on site-directed mutagenesis. The single, double, triple or quadruple PXR 
mutant was co-transfected with SUMO and PIAS plasmids in Hepa1-6 cells 
(data not shown). We revealed one potential site of human PXR SUMOylation 
at K108. By mutating K108 to arginine, the human PXR SUMO-1 and SUMO-3 
conjugation levels were significantly down-regulated. After double mutation of 
K108 and K128, the SUMO-1 modification was completely lost, whereas the 
double mutant could still form monomeric conjugates by SUMO-3. The other 
SUMO-3 site(s) besides K108 and K128 has not yet been identified. It has been 
suggested that mutation both the lysine and an adjacent acidic amino acid might 
be required to inactivate some SUMO consensus sites (210,211). Further 
experimental design of site-directed mutagenesis based on this idea may help to 
solve the puzzle. According to our current data, the possible SUMOylation 
pattern on human PXR is summarized in the Table 1.  
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Table 1.  
 
 
 
 
 
 
 
 
 
Table 1. PXR SUMOylation Pattern. The PXR protein is targeted by SUMO-1 
at two major sites, K108 and K128. SUMO-1 modification leads to monomeric 
and dimeric conjugates. The SUMO-3 modification pattern is different from 
SUMO-1. There are at least three potential sites, including K108 and K128. The 
lysine residues could support mono-, multi-mono-, and poly-SUMO-3 
conjugations of PXR.  
The identification of PXR SUMOylation sites is of great value. It will 
facilitate our understanding of PXR SUMOylation biological functions and 
physiological roles. For example, it could provide a direct and strong basis to 
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test the hypothesis that PXR SUMOylation crosstalks with other 
post-translational modifications. It has been suggested that SUMO might 
compete with ubiquitin for the same lysine (190,212). Recent studies showed 
that PXR could be ubiquitinated for eventual proteasomal degradation (213,214). 
Future immunoblot analysis using the ubiquitin antibody could be employed to 
detect the capacity of wild type and SUMO(1)yaltion-deficient K108R K128R 
double mutant for ubiquitination. The mutant variant helps to determine if 
SUMO-1 conjugation antagonizes ubiquitin modification of PXR. Other 
interesting biological abilities could also be compared between PXR 
SUMOylation-deficient mutant and wild type form, including co-regulator 
interaction, heterodimerization with RXR, sub-cellular localization, stability 
and regulation of target gene expression. 
From a more clinical perspective, a knock-in mouse model harboring the 
un-SUMOylatable form of PXR could be generated to directly assess if PXR 
SUMOylation is essential for proper physiological function. Dr. Staudinger has 
generated a PXR-deficient mouse line in 2000 (43). Recent data from our lab 
showed that the PXR null mice exhibited signs of heightened inflammation in 
their small bowels with elevated NF-κB target gene expression (132). The 
knock-in mutant mice would directly test the extent to which SUMOylation 
regulates the in vivo anti-inflammatory function of PXR. Because the 
stoichiometry of PXR SUMOylation appears exceedingly low, the forced 
over-expression of SUMO-3 and PIASy we used in the studies could potentially 
lead to the production of experimental artifacts. Therefore, the PXR 
un-SUMOylatable mutant knock-in mice would allow us to overcome certain 
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drawbacks associated with using cell culture and are promisingly beneficial to 
directly test the physiological significances of PXR SUMOylation in liver and 
small intestine.  
2. PXR Transrepression Model 
Recent studies have revealed that ligand-activated transrepression of 
inflammatory response gene by PPAR and LXRs is SUMOylation dependent 
(215,216). Our observations provide support to extend this transrepression 
pathway to an additional member of NR family: PXR. We showed that PXR 
transrepressed the induction of inflammatory response genes in Hepa1-6 cells in 
a ligand-independent manner. Since PXR was over-expressed in this case, it is 
questionable that over-expressed PXR represents the endogenous form of PXR 
in human liver cells which interacts with CCRP-HSP90 complex in the absence 
of ligand under basal condition. It is possible that PXR transrepression pathway 
is ligand-dependent in human hepatocytes because ligand activation is required 
for PXR dissociation from the CCRP-HSP90 complex and translocation to 
nucleus from cytoplasm. Taken together, our current hypothesized model is  
that  activation  of  PXR  by  xenobiotic/endogenous  compounds  leads  
to  the  SUMOylation  of  a  sub-population of this NR to stimulate the 
formation of transrepressive multi-protein complexes on the promoters of 
inflammatory response genes in liver and intestine.  
However, there are some questions regarding the transrepression 
mechanisms that remain to be answered in the future. For example, it is likely 
that reduced target gene transcription is due to the down-regulated binding 
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capacity of transcription factor to its response element. So, is NF-B DNA 
binding capacity altered in response to ligand-activated PXR SUMOylation? 
And what are the components of the co-repressor complexes formed on NF-B? 
Which protein recruits and interacts with ligand-bound SUMOylated PXR? In 
order to further validate our model, some new experimental methods may be 
required to answer those questions.  
Chromatin immunoprecipitation (ChIP) assay investigates the interaction 
between protein and DNA in the cells. Previously, ChIP assay has been used to 
detect the binding of the PXR-RXRheterodimer to the regulatory sequences of 
Cyp3a4. The result showed that NF-B activation disrupted the heterodimer 
DNA binding activity which led to suppression of PXR transcriptional activation 
(131). To further elucidate the mechanism underlying the suppression of 
pro-inflammatory gene expression by PXR activation, the ChIP assay could be 
performed to analyze NF-B DNA binding activity before and after PXR 
activation which may account for the anti-inflammatory property of PXR.  
The mammalian two hybrid assays allow us to determine the 
protein-protein interaction of human PXR with co-factors. According to our 
model, the ligand-activated PXR is SUMOylated and interacts with the 
co-repressor complexes on NF-B to inhibit the co-repressors dissociation. 
However, during PXR trans-activation, the interaction between PXR and 
co-repressors is largely down-regulated after ligand binding. We are in the 
process of resolving this puzzle based on mammalian two hybrid system. We 
hypothesize that PXR interacts with different co-repressor proteins or different 
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domains of the same co-repressor in the trans-activation and trans-repression 
pathways.  
The PXR transrepression model provides an explanation for how an 
agonist-bound PXR can be converted from an activator of gene transcription to a 
promoter-specific repressor of NF-B target genes that regulate hepatic 
inflammation. Taken together, our results suggest that activation of PXR results 
in repression of inflammatory response gene, thus providing a mechanistic 
explanation for the long-term observed immunological suppression by 
rifampicin. We hypothesize that the inflammatory stimulation leads to PXR 
SUMOylation which stabilizes the co-repressor complexes on NF-B, thereby 
causing transrepression of NF-κB signaling pathway. 
3. Clinical Significance 
Inflammatory bowel disease (IBD) is a relapsing and chronic inflammatory 
condition of the gastrointestinal tract occurring as ulcerative colitis (UC) or 
Crohn’s disease (CD) (217). UC is limited to the colon, whereas CD can affect 
any part of the gastrointestinal tract with inflammation deeper into the layers of 
the intestinal wall (218). While the physiologic etiology of IBD is unclear, the 
prevailing view is that it is triggered by multiple factors, including the 
environment, genetic variations, intestinal microbiota, and disturbances in the 
innate and adaptive immune responses (219).   Recent studies showed that 
PXR is associated with IBD and decreased expressions of PXR target genes 
cause loss of detoxification and removal of xenobiotics in the gut (220). The 
immunosuppressive and anti-inflammatory role of PXR activation provides a 
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new drug target for treating IBD. Rifaximin, a gut-specific human PXR activator, 
has been shown to be beneficial in the treatment of UC and moderate CD 
(221-223). A recent study on clinical use of rifaximin suggests that rifaximin 
down-regulates NF-B target gene expression in the PXR-dependent manner 
and protects against IBD in the patients (224). It is likely that the transrepression 
effect of NF-B signaling in IBD might be mediated by ligand-dependent 
SUMOylation of human PXR. And our study on PXR SUMOylation provides a 
molecular basis for the rifaximin treatment of IBD in the gut.  
However, the activation of PXR could lead to transactivation of PXR target 
genes that are involved in multiple physiological processes. The changes in the 
DMEs and drug transporter proteins would cause various adverse responses. One 
major side-effect of PXR activators is the ADRs. There is a clear recognition 
that the frequency of ADRs is increased in patients affected with an underlying 
systemic inflammation. The long-term treatment is often limited by adverse side 
effects believed to be caused by PXR-mediated gene transcription. This has led 
to the pursuit of compounds that retain the anti-inflammatory properties yet lack 
the adverse side effects associated with traditional PXR activators. New 
molecular insights regarding the biology of PXR SUMOylation will provide new 
opportunities to develop novel pharmacological strategies for addressing ADRs, 
and will eventually help to identify small molecules that will be used to treat 
inflammatory liver diseases. 
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4. Conclusion  
In summary, the potential for PXR SUMOylation involvement in 
inflammatory response is far-reaching and requires additional investigation to 
elucidate the specific transrepression mechanism. Regardless, PXR SUMO 
modification and/or de-SUMOylation are involved in the crosstalk with NF-B 
signaling pathway to exert its physiological functions. These studies provide 
molecular basis and the biochemical details of how PXR is converted from a 
positive regulator of drug metabolism into a transcriptional suppressor of 
inflammation in liver tissue. Novel molecules that specifically promote entry of 
PXR into the SUMOylation-dependent transrepression pathway may be of great 
therapeutic utility in liver diseases in which inflammation plays a significant 
pathogenic role.  
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